This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IPO Preview: Imperva, NewLink Genetics

NEW YORK ( TheStreet -- The IPO market is picking up again with Groupon's (GRPN - Get Report) successful debut confirming there is investor appetite for the right offerings.

Renaissance Capital notes that 11 companies are looking to make the leap next week, and if that comes to pass it will be the busiest week since November 2007.

This week's slate of new issues includes Imperva (IMPV - Get Report), a Redwood Shores, Calif.-based data security software provider that is seeking to raise $75 million. The company plans to sell 5 million shares at between $14 and $16 each, and is expected to debut on Wednesday.

Imperva targets small businesses with its on-demand web application security software with the idea that the product is cost-effective when compared to buying more hardware or hiring more IT people. The company's sales jumped $55 million for the nine months ended in September, up 45% from $38 million in the same period a year earlier. Despite the revenue jump though, Imperva's loss hasn't narrowed much at all, totaling $8.7 million for the latest nine-month period vs. a loss of $8.9 million in the same stretch the previous year.

Imperva mostly wants investors to look at its deferred revenue, which is the money it has invoiced but hasn't actually received yet. Deferred revenue, which is based on maintenance and support contracts, sat at $19.1 million for the nine months ended Sept. 30, up 39% from its 2010 total $13.7 million, according to the company's latest S-1 filing with the Securities and Exchange Commission.

If investors are looking at Imperva's products as a gauge of whether to buy the new stock, the IPO may be a bit of a tough sell. As the company states in its filing, "We have limited historic financial data, and we operate in a rapidly evolving market, and as such, any predictions about our future revenue and expenses may not be as accurate as they would be if we had a longer operating history or operated in a more predictable market."

Hacker fear though is driving the data security market, which is expected to grow to $38 billion in 2014 from $27 billion in 2010. As of March, Imperva has three issued patents and seven pending patents, which isn't considered to be a large number when compared to its competition, which includes IBM (symbol) and EMC (symbol). The Imperva deal is rumored to be oversubscribed, and Francis Gaskins, IPO Desktop's president, believes investors should stay on the sidelines.

"Unless they have a big uptick from here on, it looks like it's hard to get to cash flow break even for them," said Gaskins.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $158.30 0.00%
CELG $103.41 0.00%
EMC $26.11 0.00%
GRPN $3.62 0.00%
IBM $145.94 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs